A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Stopped early · Phase 1/Phase 2

Conditions studied: Homozygous Familial Hypercholesterolemia (HoFH)

In brief

This first-in-human study is intended to evaluate the safety and preliminary effectiveness of AAV (Adeno-associated virus)-based liver-directed gene therapy in the treatment of adults with Homozygous Familial Hypercholesterolemia (HoFH).

Key facts

Study ID
NCT02651675
Run by
REGENXBIO Inc.
People needed
9
Starts
2016-03-01
Expected to finish
2020-11-27
Last updated by the study team
2023-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.